Latest News & Features
Americas
Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew. 7 January 2021
Americas
Chemical manufacturers have a renewed opportunity to protect the confidentiality of the chemicals they make or import, according to an announcement by the US Environmental Protection Agency. 7 January 2021
Big Pharma
A licensing pathway that will reduce the time it takes for novel medicines to enter the marketplace has been launched by the UK Medicines and Healthcare products Regulatory Agency. 7 January 2021
article
There is an increasing area of convergence between high-tech AI and Life Sciences leading to some interesting developments in the administration of IP. So, what does this mean for IP portfolio strategy? 7 January 2021
Americas
Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status. 7 January 2021
Asia
India has granted emergency approval to COVID-19 vaccines developed by AstraZeneca and Oxford University and one from the state-run institute Bharat Biotech, ahead of a huge immunisation drive that is planned to begin this week. 5 January 2021
Americas
Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31. 5 January 2021
Americas
Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management. 5 January 2021
Americas
One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation. 5 January 2021
Americas
Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation. 24 December 2020